DOCSLIB.ORG

Article in Press

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

G Model MIMM-4561; No. of Pages 12 ARTICLE IN PRESS Molecular Immunology xxx (2015) xxx–xxx Contents lists available at ScienceDirect Molecular Immunology j ournal homepage: www.elsevier.com/locate/molimm Review Alternative molecular formats and therapeutic applications for ଝ bispecific antibodies ∗ Christoph Spiess, Qianting Zhai, Paul J. Carter Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA a r t i c l e i n f o a b s t r a c t Article history: Bispecific antibodies are on the cusp of coming of age as therapeutics more than half a century after they Received 28 November 2014 ® were first described. Two bispecific antibodies, catumaxomab (Removab , anti-EpCAM × anti-CD3) and Received in revised form ® blinatumomab (Blincyto , anti-CD19 × anti-CD3) are approved for therapy, and >30 additional bispecific 30 December 2014 antibodies are currently in clinical development. Many of these investigational bispecific antibody drugs Accepted 2 January 2015 are designed to retarget T cells to kill tumor cells, whereas most others are intended to interact with two Available online xxx different disease mediators such as cell surface receptors, soluble ligands and other proteins. The modular architecture of antibodies has been exploited to create more than 60 different bispecific antibody formats. Keywords: These formats vary in many ways including their molecular weight, number of antigen-binding sites, Bispecific antibodies spatial relationship between different binding sites, valency for each antigen, ability to support secondary Antibody engineering Antibody therapeutics immune functions and pharmacokinetic half-life. These diverse formats provide great opportunity to tailor the design of bispecific antibodies to match the proposed mechanisms of action and the intended clinical application. © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1. Introduction first demonstrated more than 50 years ago (Nisonoff and Rivers, 1961). Engineering monospecific antibodies for bispecificity opens Antibodies are a well established and rapidly growing drug class up many new potential therapeutic applications as evidenced by with at least 45 antibody-based products currently marketed for >30 BsAb in clinical development (Table 1). Here we review the ∼ imaging or therapy in the USA and/or Europe with 63 billion USD rationale for making BsAb, criteria for selection of molecular format in total worldwide sales in 2013 (Ecker et al., 2014; Walsh, 2014) from a plethora of alternatives and potential therapeutic applica- (antibodysociety.org). This major clinical and commercial success tions. with antibody therapeutics has fueled much interest in develop- ing next generation antibody drugs including bispecific antibodies 2. Alternative formats for BsAb (Chan and Carter, 2010; Kontermann, 2012; Byrne et al., 2013). As their name implies, bispecific antibodies (BsAb) bind to two dif- The modular architecture of immunoglobulins has been ferent antigens, or two different epitopes on the same antigen, as exploited to create a growing number (>60) of alternative BsAb for- mats (Chan and Carter, 2010; Kontermann, 2012; Byrne et al., 2013; Jost and Plückthun, 2014). BsAb are classified here into five dis- tinct structural groups: (i) bispecific IgG (BsIgG) (ii) IgG appended Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ADCP, with an additional antigen-binding moiety (iii) BsAb fragments (iv) antibody-dependent cellular phagocytosis; ALL, acute lymphoblastic leukemia; AMD, age-related macular degeneration; AML, acute myeloid leukemia; BsAb, bispe- bispecific fusion proteins and (v) BsAb conjugates (Fig. 1). Each of cific antibody; BsIgG, bispecific IgG; CDC, complement-dependent cytotoxicity; CEA, these different BsAb formats brings different properties in bind- carcinoembryonic antigen; CLL, chronic lymphocytic leukemia; DAF, dual action ing valency for each antigen, geometry of antigen-binding sites, Fab; DART, dual-affinity retargeting; DLBCL, diffuse large B-cell lymphoma; FDA, pharmacokinetic half-life and in some cases effector functions. Food and Drug Administration; ImmTACs, immune-mobilizing monoclonal T cell receptors against cancer; MAPG, melanoma-associated proteoglycan; NHL, non- Hodgkin’s lymphoma. ଝ 2.1. Bispecific antibodies with IgG-like structure This article belongs to Special Issue on Therapeutic Antibodies. ∗ Corresponding author. Tel.: +1 650 467 4371. Bispecific IgG (BsIgG) is a commonly used BsAb format that E-mail addresses: [email protected] (C. Spiess), [email protected] (Q. Zhai), [email protected] (P.J. Carter). is monovalent for each antigen (1 + 1 antigen-binding valency). http://dx.doi.org/10.1016/j.molimm.2015.01.003 0161-5890/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Please cite this article in press as: Spiess, C., et al., Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol. Immunol. (2015), http://dx.doi.org/10.1016/j.molimm.2015.01.003 MIMM-4561; 2 G Model Please Mol. Table 1 Bispecific antibodies and other bispecific immunotherapeutics in clinical development. Immunol. cite BsAb (other names, sponsoring organizations) BsAb format Targets Proposed mechanisms of action Development Diseases (or healthy volunteers) stages No. this ® of Catumaxomab (Removab , Fresenius Biotech, BsIgG: Triomab CD3, EpCAM Retargeting of T cells to tumor, Fc Approved in EU Malignant ascites in EpCAM positive (2015), article Pages Trion Pharma, Neopharm) mediated effector functions tumors Ertumaxomab (Neovii Biotech, Fresenius Biotech) BsIgG: Triomab CD3, HER2 Retargeting of T cells to tumor Phase I/II Advanced solid tumors 12 in ® http://dx.doi.org/10.1016/j.molimm.2015.01.003 Blinatumomab (Blincyto , AMG 103, MT 103, BiTE CD3, CD19 Retargeting of T cells to tumor Approved in USA Precursor B-cell ALL press MEDI 538, Amgen) Phase II and III ALL Phase II DLBCL Phase I NHL as: Solitomab (AMG 110, MT110, Amgen) BiTE CD3, EpCAM Retargeting of T cells to tumor Phase I Solid tumors Spiess, MEDI 565 (AMG 211, MedImmune, Amgen) BiTE CD3, CEA Retargeting of T cells to tumor Phase I Gastrointestinal adenocancinoma BAY2010112 (AMG 212, Bayer; Amgen) BiTE CD3, PSMA Retargeting of T cells to tumor Phase I Prostate cancer C., ARTICLE INPRESS ARTICLE et MGD006 (Macrogenics) DART CD3, CD123 Retargeting of T cells to tumor Phase I AML C. Spiess al., MGD007 (Macrogenics) DART CD3, gpA33 Retargeting of T cells to tumor Phase I Colorectal cancer Alternative et AFM11 (Affimed Therapeutics) TandAb CD3, CD19 Retargeting of T cells to tumor Phase I NHL and ALL al. AFM13 (Affimed Therapeutics) TandAb CD30, CD16A Retargeting of NK cells to tumor cells Phase II Hodgkin’s Lymphoma / Molecular GD2 (Barbara Ann Karmanos Cancer Institute) T cells preloaded with CD3, GD2 Retargeting of T cells to tumor Phase I/II Neuroblastoma and osteosarcoma BsAb molecular pGD2 (Barbara Ann Karmanos Cancer Institute) T cells preloaded with CD3, Her2 Retargeting of T cells to tumor Phase II Metastatic breast cancer Immunology BsAb EGFRBi-armed autologous activated T cells (Roger T cells preloaded with CD3, EGFR Autologous activated T cells to Phase I Lung and other solid tumors formats Williams Medical Center) BsAb EGFR-positive tumor xxx Anti-EGFR-armed activated T-cells (Barbara Ann T cells preloaded with CD3, EGFR Autologous activated T cells to Phase I Colon and pancreatic cancers (2015) Karmanos Cancer Institute) BsAb EGFR-positive tumor and rM28 (University Hospital Tübingen) Tandem scFv CD28, MAPG Retargeting of T cells to tumor Phase II Metastatic melanoma xxx–xxx therapeutic IMCgp100 (Immunocore) ImmTAC CD3, peptide MHC Retargeting of T cells to tumor Phase I/II Metastatic melanoma DT2219ARL (NCI, University of Minnesota) 2 scFv linked to CD19, CD22 Targeting of protein toxin to tumor Phase IBcell leukemia diphtheria toxin or lymphoma Duligotuzumab (MEHD7945A, Genentech, Roche) DAF EGFR, HER3 Blockade of 2 receptors, ADCC Phase I and II Head and neck cancer applications Phase II Colorectal cancer LY3164530 (Eli Lily) Not disclosed EGFR, MET Blockade of 2 receptors Phase I Advanced or metastatic cancer MM-111 (Merrimack Pharmaceuticals) HSA body HER2, HER3 Blockade of 2 receptors Phase II Gastric and esophageal cancers Phase I Breast cancer for MM-141, (Merrimack Pharmaceuticals) IgG-scFv IGF-1R, HER3 Blockade of 2 receptors Phase I Advanced solid tumors bispecific RG7221 (RO5520985, Roche) CrossMab Ang2, VEGF A Blockade of 2 proangiogenics Phase I Solid tumors RG7716 (Roche) CrossMab Ang2, VEGF A Blockade of 2 proangiogenics Phase I Wet AMD TF2 (Immunomedics) Dock and lock CEA, HSG Pretargeting tumor for PET or radioimaging Phase II Colorectal, breast and lung cancers antibodies. ABT-981 (AbbVie) DVD-Ig IL-1␣, IL-1␤ Blockade of 2 proinflammatory cytokines Phase II Osteoarthritis ABT-122 (AbbVie) DVD-Ig TNF, IL-17A Blockade of 2 proinflammatory cytokines Phase II Rheumatoid arthritis COVA322 IgG-fynomer TNF, IL17A Blockade of 2 proinflammatory cytokines Phase I/II Plaque psoriasis G Model MIMM-4561; No. of Pages 12 ARTICLE IN PRESS C. Spiess et al. / Molecular Immunology xxx (2015) xxx–xxx 3 Production of BsIgG by co-expression of the two light and two action heavy chains in a single host cell can be highly challenging because of the low yield of desired BsIgG and the difficulty in removing dual
Recommended publications
  • Affibody Molecules for Epidermal Growth Factor Receptor Targeting

    Affibody Molecules for Epidermal Growth Factor Receptor Targeting

    Journal of Nuclear Medicine, published on January 21, 2009 as doi:10.2967/jnumed.108.055525 Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry Vladimir Tolmachev1-3, Mikaela Friedman4, Mattias Sandstrom¨ 5, Tove L.J. Eriksson2, Daniel Rosik2, Monika Hodik1, Stefan Sta˚hl4, Fredrik Y. Frejd1,2, and Anna Orlova1,2 1Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden; 2Affibody AB, Bromma, Sweden; 3Department of Medical Sciences, Nuclear Medicine, Uppsala University, Uppsala, Sweden; 4Division of Molecular Biotechnology, School of Biotechnology, Royal Institute of Technology, Stockholm, Sweden; and 5Section of Hospital Physics, Department of Oncology, Uppsala University Hospital, Uppsala, Sweden Noninvasive detection of epidermal growth factor receptor (EGFR) expression in malignant tumors by radionuclide molecu- he epidermal growth factor receptor (EGFR; other lar imaging may provide diagnostic information influencing pa- T designations are HER1 and ErbB-1) is a transmembrane tient management. The aim of this study was to evaluate a tyrosine kinase receptor that regulates cell proliferation, novel EGFR-targeting protein, the ZEGFR:1907 Affibody molecule, for radionuclide imaging of EGFR expression, to determine a motility, and suppression of apoptosis (1). Overexpression suitable tracer format (dimer or monomer) and optimal label. of EGFR is documented in several malignant tumors, such Methods: An EGFR-specific Affibody molecule, ZEGFR:1907, as carcinomas of the breast, urinary bladder, and lung, and 111 and its dimeric form, (ZEGFR:1907)2, were labeled with In using is associated with poor prognosis (2). A high level of EGFR 125 benzyl-diethylenetriaminepentaacetic acid and with I using expression could provide malignant cells with an advantage p-iodobenzoate.
  • Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases

    Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases

    Antibodies 2015, 4, 170-196; doi:10.3390/antib4030170 OPEN ACCESS antibodies ISSN 2073-4468 www.mdpi.com/journal/antibodies Review Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases Marta Westwood * and Alastair D. G. Lawson Structural Biology, UCB, 216 Bath Road, Slough, SL1 3WE UK; E-Mail: [email protected]. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +44-1-753-534-655 (ext.7749); Fax: +44-1-753-536-632. Academic Editor: Dimiter S. Dimitrov Received: 13 May 2015 / Accepted: 9 July 2015 / Published: 15 July 2015 Abstract: Assembly of misfolded proteins into fibrillar deposits is a common feature of many neurodegenerative diseases. Developing effective therapies to these complex, and not yet fully understood diseases is currently one of the greatest medical challenges facing society. Slow and initially asymptomatic onset of neurodegenerative disorders requires profound understanding of the processes occurring at early stages of the disease including identification and structural characterisation of initial toxic species underlying neurodegeneration. In this review, we chart the latest progress made towards understanding the multifactorial process leading to amyloid formation and highlight efforts made in the development of therapeutic antibodies for the treatment of amyloid-based disorders. The specificity and selectivity of conformational antibodies make them attractive research probes to differentiate between transient states preceding formation of mature fibrils and enable strategies for potential therapeutic intervention to be considered. Keywords: antibody; amyloids; conformation; prion; Alzheimer’s; Parkinson’s; fibrils, tau; Huntingtin; protein misfolding 1. Introduction Correct protein folding is crucial for maintaining healthy biological functions.
  • Rapid Selection of Specific MAP Kinase-Binders from Designed Ankyrin Repeat Protein Libraries

    Rapid Selection of Specific MAP Kinase-Binders from Designed Ankyrin Repeat Protein Libraries

    Protein Engineering, Design & Selection vol. 19 no. 5 pp. 219–229, 2006 Published online March 21, 2006 doi:10.1093/protein/gzl004 Rapid selection of specific MAP kinase-binders from designed ankyrin repeat protein libraries Patrick Amstutz1,4,5, Holger Koch1,4, H. Kaspar Binz1, form in this milieu. For this reason, antibodies were Stefan A. Deuber2 and Andreas Plu¨ckthun1,3 engineered for higher intracellular stability with some success 1 et al ¨ ¨ Biochemisches Institut der Universita¨tZu¨rich, Winterthurerstrasse 190, (Proba ., 1998; Worn and Pluckthun, 1998; Desiderio CH-8057 Zu¨rich, Switzerland and 2Institut fu¨r Medizinische Virologie der et al., 2001; Visintin et al., 2002), but the number of selected Universita¨tZu¨rich, Gloriastrasse 30, Zu¨rich, Switzerland and active binders is usually limited (Tanaka and Rabbitts, 3To whom correspondence should be addressed. 2003; Koch et al., 2006). These results can be explained by E-mail: [email protected] the selection pressure, which not only places demands on 4These authors contributed equally to this work. 5 specific binding but also requires stability under reducing Present address: Molecular Partners AG, c/o Universita¨tZu¨rich, conditions. Winterthurerstrasse 190, CH-8057 Zu¨rich, Switzerland To overcome these limitations of immunoglobulin We describe here the rapid selection of specific MAP-kinase domains, a variety of novel scaffolds for the generation of binders from a combinatorial library of designed ankyrin antibody-like binding molecules, some of them possessing repeat proteins (DARPins). A combined in vitro/in vivo selec- very favorable biophysical properties, has been developed tion approach, based on ribosome display and the protein (Nygren and Skerra, 2004; Binz et al., 2005).
  • Nanobodies Right in the Middle: Intrabodies As Toolbox to Visualize and Modulate Antigens in the Living Cell

    Nanobodies Right in the Middle: Intrabodies As Toolbox to Visualize and Modulate Antigens in the Living Cell

    biomolecules Review Nanobodies Right in the Middle: Intrabodies as Toolbox to Visualize and Modulate Antigens in the Living Cell Teresa R. Wagner 1,2 and Ulrich Rothbauer 1,2,* 1 Pharmaceutical Biotechnology, Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany; [email protected] 2 Natural and Medical Sciences Institute, University of Tuebingen, 72770 Reutlingen, Germany * Correspondence: [email protected]; Tel.: +49-7121-5153-0415; Fax: +49-7121-5153-0816 Received: 30 November 2020; Accepted: 18 December 2020; Published: 21 December 2020 Abstract: In biomedical research, there is an ongoing demand for new technologies to elucidate disease mechanisms and develop novel therapeutics. This requires comprehensive understanding of cellular processes and their pathophysiology based on reliable information on abundance, localization, post-translational modifications and dynamic interactions of cellular components. Traceable intracellular binding molecules provide new opportunities for real-time cellular diagnostics. Most prominently, intrabodies derived from antibody fragments of heavy-chain only antibodies of camelids (nanobodies) have emerged as highly versatile and attractive probes to study and manipulate antigens within the context of living cells. In this review, we provide an overview on the selection, delivery and usage of intrabodies to visualize and monitor cellular antigens in living cells and organisms. Additionally, we summarize recent advances in the development of intrabodies as cellular biosensors and their application to manipulate disease-related cellular processes. Finally, we highlight switchable intrabodies, which open entirely new possibilities for real-time cell-based diagnostics including live-cell imaging, target validation and generation of precisely controllable binding reagents for future therapeutic applications. Keywords: nanobody; intrabody; phage display; live-cell imaging; biosensors; target validation 1.
  • Designer Oncolytic Adenovirus: Coming of Age

    Designer Oncolytic Adenovirus: Coming of Age

    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Designer Oncolytic Adenovirus: Coming of Age Alexander T. Baker1, Carmen Aguirre-Hernandez2, Gunnel Hallden2, Alan L. Parker1* 1 Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, CF14 4XN, United Kingdom 2 Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, EC1M 6BQ, United Kingdom *Corresponding author Dr. Alan L. Parker Division of Cancer and Genetics Henry Wellcome Building Cardiff University School of Medicine Heath Park Cardiff CF14 4XN Email: [email protected] Keywords: adenovirus; oncolytic; targeting; virotherapy; cancer; αvβ6 integrin; immunotherapy; tropism 1 © 2018 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 21 May 2018 doi:10.20944/preprints201805.0273.v1 Contents 1. Introduction: ................................................................................................................................... 4 2. Replication-selective adenoviruses ..................................................................................................... 6 2.1 Combination of oncolytic adenoviruses with chemotherapy ..................................................... 11 3. Oncolytic immunotherapy ................................................................................................................ 12 4. Tropism modification strategies ......................................................................................................
  • Targeting Ras with Macromolecules

    Targeting Ras with Macromolecules

    Downloaded from http://perspectivesinmedicine.cshlp.org/ on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Targeting Ras with Macromolecules Dehua Pei, Kuangyu Chen, and Hui Liao Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio 43210 Correspondence: [email protected] Activating Ras mutations are associated with 30% of all human cancers and the four Ras isoforms are highly attractive targets for anticancer drug discovery. However, Ras proteins are challenging targets for conventional drug discovery because they function through intracel- lular protein–protein interactions and their surfaces lack major pockets for small molecules to bind. Over the past few years, researchers have explored a variety of approaches and modalities, with the aim of specifically targeting oncogenic Ras mutants for anticancer treatment. This perspective will provide an overview of the efforts on developing “macro- molecular” inhibitors against Ras proteins, including peptides, macrocycles, antibodies, nonimmunoglobulin proteins, and nucleic acids. as is a small GTPase, acting as a molecular Mutations in K-Ras are particularly prevalent in Rswitch in many signaling pathways and some of the most deadly cancers, including pan- regulating cell proliferation, differentiation, creatic (90% prevalence), colon (35% preva- and survival, among other functions (Young lence), and lung cancers (16% prevalence). Dis- et al. 2009). Its four isoforms, H-Ras, N-Ras, ruption of Ras function genetically (i.e., by gene K-Ras4A, and K-Ras4B, are identical within mutations or small-interfering RNA [siRNA]) the amino-terminal 85 amino acids and differ inhibits the proliferation of Ras-mutant cancer primarily in the carboxyl-termini (amino acids cells and induces apoptosis, validating Ras as 165–189).
  • Strategies for Selecting Membrane Protein-Specific Antibodies Using Phage Display with Cell-Based Panning

    Strategies for Selecting Membrane Protein-Specific Antibodies Using Phage Display with Cell-Based Panning

    antibodies Review Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning Mohamed A. Alfaleh 1,2,* ID , Martina L. Jones 1,3,* ID , Christopher B. Howard 1,3,4 and Stephen M. Mahler 1,3 1 Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland 4072, Australia; [email protected] (C.B.H.); [email protected] (S.M.M) 2 Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia 3 Australian Research Council Training Centre for Biopharmaceutical Innovation, The University of Queensland, Brisbane, Queensland 4072, Australia 4 Centre for Advanced Imaging, The University of Queensland, Brisbane, Queensland 4072, Australia * Correspondence: [email protected] (M.A.A.); [email protected] (M.L.J.); Tel.: +61-733-463-178 (M.L.J.) Academic Editor: Dimiter S. Dimitrov Received: 14 June 2017; Accepted: 7 July 2017; Published: 5 August 2017 Abstract: Membrane proteins are attractive targets for monoclonal antibody (mAb) discovery and development. Although several approved mAbs against membrane proteins have been isolated from phage antibody libraries, the process is challenging, as it requires the presentation of a correctly folded protein to screen the antibody library. Cell-based panning could represent the optimal method for antibody discovery against membrane proteins, since it allows for presentation in their natural conformation along with the appropriate post-translational modifications. Nevertheless, screening antibodies against a desired antigen, within a selected cell line, may be difficult due to the abundance of irrelevant organic molecules, which can potentially obscure the antigen of interest.
  • A Genetically-Encoded Toolkit of Functionalized Nanobodies Against Fluorescent Proteins

    A Genetically-Encoded Toolkit of Functionalized Nanobodies Against Fluorescent Proteins

    bioRxiv preprint doi: https://doi.org/10.1101/544700; this version posted April 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A genetically-encoded toolkit of functionalized nanobodies against fluorescent proteins 2 for visualizing and manipulating intracellular signalling 3 4 David L. Prole1,* and Colin W. Taylor1,* 5 1Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge 6 CB2 1PD, United Kingdom 7 8 *For correspondence: [email protected], [email protected] 9 10 Short title 11 Functionalized nanobodies for studying intracellular signalling 12 13 Keywords: cell signalling, endoplasmic reticulum, fluorescence microscopy, fluorescent 14 protein, GFP, intrabody, membrane contact site, mitochondria, nanobody, RFP. 1 bioRxiv preprint doi: https://doi.org/10.1101/544700; this version posted April 26, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 15 Abbreviations 2+ 2+ 16 BFP, blue fluorescent protein; [Ca ]c, cytosolic free Ca concentration; CALI, 17 chromophore-assisted light inactivation; CaM, calmodulin; CFP, cyan fluorescent protein; 18 ER, endoplasmic reticulum; FKBP, FK506-binding protein; FRB, FKBP-rapamycin-binding 19 domain; FP, fluorescent protein; GFP, green fluorescent protein; GNb, GFP-binding 20 nanobody; HBS, HEPES-buffered saline; IP3R, inositol 1,4,5-trisphosphate receptor; 21 LAMP1, lysosomal membrane protein 1; mCherry, monomeric Cherry; MCS, membrane 22 contact site; MHBS, modified HBS; MP, multimerizing protein; mRFP, monomeric red 23 fluorescent protein; OMM, outer mitochondrial membrane; PM, plasma membrane; RFP, red 24 fluorescent protein; RNb, RFP-binding nanobody; ROI, region of interest; SOCE, store- 25 operated Ca2+ entry; TIRFM, total internal reflection fluorescence microscopy; YFP, yellow 26 fluorescent protein.
  • Advances in Targeted Degradation of Endogenous Proteins Roth, Sascha; Fulcher, Luke; Sapkota, Gopal

    Advances in Targeted Degradation of Endogenous Proteins Roth, Sascha; Fulcher, Luke; Sapkota, Gopal

    University of Dundee Advances in targeted degradation of endogenous proteins Roth, Sascha; Fulcher, Luke; Sapkota, Gopal Published in: Cellular and Molecular Life Sciences DOI: 10.1007/s00018-019-03112-6 Publication date: 2019 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Roth, S., Fulcher, L., & Sapkota, G. (2019). Advances in targeted degradation of endogenous proteins. Cellular and Molecular Life Sciences, 76(14), 2761-2777. https://doi.org/10.1007/s00018-019-03112-6 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 29. Sep. 2021 Cellular and Molecular Life Sciences https://doi.org/10.1007/s00018-019-03112-6 Cellular andMolecular Life Sciences REVIEW Advances in targeted degradation of endogenous proteins Sascha Röth1 · Luke J. Fulcher1 · Gopal P. Sapkota1 Received: 11 January 2019 / Revised: 23 March 2019 / Accepted: 16 April 2019 © The Author(s) 2019 Abstract Protein silencing is often employed as a means to aid investigations in protein function and is increasingly desired as a thera- peutic approach.
  • An Affibody Molecule Is Actively Transported Into the Cerebrospinal

    An Affibody Molecule Is Actively Transported Into the Cerebrospinal

    International Journal of Molecular Sciences Article An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor Sebastian W. Meister , Linnea C. Hjelm , Melanie Dannemeyer, Hanna Tegel, Hanna Lindberg, Stefan Ståhl and John Löfblom * Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Centre, SE-106 91 Stockholm, Sweden; [email protected] (S.W.M.); [email protected] (L.C.H.); [email protected] (M.D.); [email protected] (H.T.); [email protected] (H.L.); [email protected] (S.S.) * Correspondence: [email protected]; Tel.: +46-8-790-9659 Received: 6 March 2020; Accepted: 22 April 2020; Published: 23 April 2020 Abstract: The use of biotherapeutics for the treatment of diseases of the central nervous system (CNS) is typically impeded by insufficient transport across the blood–brain barrier. Here, we investigate a strategy to potentially increase the uptake into the CNS of an affibody molecule (ZSYM73) via binding to the transferrin receptor (TfR). ZSYM73 binds monomeric amyloid beta, a peptide involved in Alzheimer’s disease pathogenesis, with subnanomolar affinity. We generated a tri-specific fusion protein by genetically linking a single-chain variable fragment of the TfR-binding antibody 8D3 and an albumin-binding domain to the affibody molecule ZSYM73. Simultaneous tri-specific target engagement was confirmed in a biosensor experiment and the affinity for murine TfR was determined to 5 nM. Blockable binding to TfR on endothelial cells was demonstrated using flow cytometry and in a preclinical study we observed increased uptake of the tri-specific fusion protein into the cerebrospinal fluid 24 h after injection.
  • WO 2019/068007 Al Figure 2

    WO 2019/068007 Al Figure 2

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2019/068007 Al 04 April 2019 (04.04.2019) W 1P O PCT (51) International Patent Classification: (72) Inventors; and C12N 15/10 (2006.01) C07K 16/28 (2006.01) (71) Applicants: GROSS, Gideon [EVIL]; IE-1-5 Address C12N 5/10 (2006.0 1) C12Q 1/6809 (20 18.0 1) M.P. Korazim, 1292200 Moshav Almagor (IL). GIBSON, C07K 14/705 (2006.01) A61P 35/00 (2006.01) Will [US/US]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., C07K 14/725 (2006.01) P.O. Box 4044, 7403635 Ness Ziona (TL). DAHARY, Dvir [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (21) International Application Number: Box 4044, 7403635 Ness Ziona (IL). BEIMAN, Merav PCT/US2018/053583 [EilL]; c/o ImmPACT-Bio Ltd., 2 Ilian Ramon St., P.O. (22) International Filing Date: Box 4044, 7403635 Ness Ziona (E.). 28 September 2018 (28.09.2018) (74) Agent: MACDOUGALL, Christina, A. et al; Morgan, (25) Filing Language: English Lewis & Bockius LLP, One Market, Spear Tower, SanFran- cisco, CA 94105 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 62/564,454 28 September 2017 (28.09.2017) US AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 62/649,429 28 March 2018 (28.03.2018) US CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (71) Applicant: IMMP ACT-BIO LTD.
  • PET Imaging of HER2-Positive Tumors with Cu-64-Labeled

    PET Imaging of HER2-Positive Tumors with Cu-64-Labeled

    Mol Imaging Biol (2019) 21:907Y916 DOI: 10.1007/s11307-018-01310-5 * World Molecular Imaging Society, 2019 Published Online: 7 January 2019 RESEARCH ARTICLE PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules Shibo Qi,1,2 Susan Hoppmann,2 Yingding Xu,2 Zhen Cheng 2 1School of Environmental and Chemical Engineering, Tianjin Polytechnic University, Tianjin, 300387, China 2Molecular Imaging Program at Stanford (MIPS), Department of Radiology, and Bio-X Program, Canary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, 94305-5344, USA Abstract Purpose: Previous studies has demonstrated the utility of human epidermal growth factor receptor type 2 (HER2) as an attractive target for cancer molecular imaging and therapy. An affibody protein with strong binding affinity for HER2, ZHER2:342, has been reported. Various methods of chelator conjugation for radiolabeling HER2 affibody molecules have been described in the literature including N-terminal conjugation, C-terminal conjugation, and other methods. Cu-64 has recently been extensively evaluated due to its half-life, decay properties, and availability. Our goal was to optimize the radiolabeling method of this affibody molecule with Cu- 64, and translate a positron emission tomography (PET) probe with the best in vivo performance to clinical PET imaging of HER2-positive cancers. Procedures: In our study, three anti-HER2 affibody proteins-based PET probes were prepared, and their in vivo performance was evaluated in mice bearing HER2-positive subcutaneous 39 SKOV3 tumors. The affibody analogues, Ac-Cys-ZHER2:342,Ac-ZHER2:342(Cys ), and Ac- ZHER2:342-Cys, were synthesized using the solid phase peptide synthesis method.